Version 1
: Received: 11 February 2020 / Approved: 11 February 2020 / Online: 11 February 2020 (11:54:03 CET)
Version 2
: Received: 4 March 2020 / Approved: 4 March 2020 / Online: 4 March 2020 (11:08:41 CET)
Version 3
: Received: 19 March 2020 / Approved: 20 March 2020 / Online: 20 March 2020 (09:31:54 CET)
Version 4
: Received: 27 January 2021 / Approved: 1 February 2021 / Online: 1 February 2021 (16:07:55 CET)
How to cite:
Kovesdi, I.; Ranst, M.V.; Chumakov, P.M.; Sandig, V.; Bakacs, T. The Clinically Validated Viral Superinfection Therapy (SIT) Platform Technology May Mitigate Severe Cases of COVID-19 Infections. Preprints2020, 2020020147. https://doi.org/10.20944/preprints202002.0147.v2
Kovesdi, I.; Ranst, M.V.; Chumakov, P.M.; Sandig, V.; Bakacs, T. The Clinically Validated Viral Superinfection Therapy (SIT) Platform Technology May Mitigate Severe Cases of COVID-19 Infections. Preprints 2020, 2020020147. https://doi.org/10.20944/preprints202002.0147.v2
Kovesdi, I.; Ranst, M.V.; Chumakov, P.M.; Sandig, V.; Bakacs, T. The Clinically Validated Viral Superinfection Therapy (SIT) Platform Technology May Mitigate Severe Cases of COVID-19 Infections. Preprints2020, 2020020147. https://doi.org/10.20944/preprints202002.0147.v2
APA Style
Kovesdi, I., Ranst, M.V., Chumakov, P.M., Sandig, V., & Bakacs, T. (2020). The Clinically Validated Viral Superinfection Therapy (SIT) Platform Technology May Mitigate Severe Cases of COVID-19 Infections. Preprints. https://doi.org/10.20944/preprints202002.0147.v2
Chicago/Turabian Style
Kovesdi, I., Volker Sandig and Tibor Bakacs. 2020 "The Clinically Validated Viral Superinfection Therapy (SIT) Platform Technology May Mitigate Severe Cases of COVID-19 Infections" Preprints. https://doi.org/10.20944/preprints202002.0147.v2
Abstract
The transmission characteristic of COVID-19 is of similar magnitude to severe acute respiratory syndrome-related coronavirus (SARS-CoV) and the 1918 pandemic influenza. The virus is now in 50 countries and on nearly all continents. The World Health Organization (WHO) says to prepare for a pandemic. There is no current evidence from random clinical trials (RCTs) to recommend any specific anti-COVID-19 treatment for patients with suspected or confirmed COVID-19 infection. In order to mitigate the impact of the COVID-19 outbreak, here we propose an innovative superinfection therapeutic (SIT) strategy, which could complement the development of prophylactic vaccines. SIT is based on clinical observations that unrelated viruses might interact in co-infected patients. During SIT, the patient benefit from superinfection with an apathogenic dsRNA virus such as the infectious bursal disease virus (IBDV), which is a powerful activator of the interferon-dependent antiviral gene program. An attenuated vaccine strain of IBDV was already successfully administered to resolve acute and persistent infections induced by two completely different viruses, the hepatitis B (DNA) and C (RNA) viruses (HBV/HCV). Importantly, the epidemiological efficacy of a similar strategy to SIT had already been successfully tested in large controlled trials. Standard live orally administered enterovirus vaccines that stimulate the production of endogenous interferon of the host mitigated the seasonal outbreaks of influenza and other associated acute respiratory infections in 152,042 individuals without adverse reactions.
Medicine and Pharmacology, Epidemiology and Infectious Diseases
Copyright:
This is an open access article distributed under the Creative Commons Attribution License which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.
Received:
4 March 2020
Commenter:
Tibor Bakacs
Commenter's Conflict of Interests:
Author
Comment:
The epidemiological efficacy of a similar strategy to SIT had already been successfully tested in large controlled trials. Standard live orally administered enterovirus vaccines that stimulate the production of endogenous interferon of the host mitigated the seasonal outbreaks of influenza and other associated acute respiratory infections in 152,042 individuals without adverse reactions.
Commenter: Tibor Bakacs
Commenter's Conflict of Interests: Author